What U.S. Government Contractors and Grant Recipients Need To Know About Terminations, Stop Work Orders, Tariffs, and the Path Forward in 2025
Client Alert | 1 min read | 02.07.25
On February 6, 2025, Crowell & Moring presented a webinar, "The New Normal: What U.S. Government Contractors and Grant Recipients Need to Know About Terminations, Stop Work Orders, Tariffs, and the Path Forward in 2025." In this webinar (available here), Crowell & Moring lawyers specializing in U.S. government contracts and grants addressed:
- Stop Work Orders
- De-Scoping Contracts and Grants
- Partial and Full Terminations for Convenience
- Non-Payment and Other Breaches
- The Impact of New Tariffs
Specifically, the discussion focused on potential government actions contractors and grant recipients can expect given recent developments, and the steps that contractors and grant recipients can take now to preserve their rights and protect the bottom line. This includes responding to and negotiating with government counterparties, providing notice where required, and thinking about cost recovery strategies.
Contacts
Associate
She/Her/Hers
Insights
Client Alert | 4 min read | 04.10.25
Hikma and Amici Curiae Ask Supreme Court to Revisit Induced Infringement by Generic “Skinny Labels”
In Amarin Pharma, Inc. v. Hikma Pharms. USA Inc., C.A. No. 20-1630 (D. Del.), brand manufacturer Amarin brought an induced infringement claim against Hikma’s generic icosapent ethyl product, which lists Amarin’s Vascepa® as the reference listed drug. Vascepa was originally approved by the U.S. Food and Drug Administration (“FDA”) to treat severe hypertriglyceridemia, and later, Amarin obtained patents and approval for Vascepa as a treatment to reduce cardiovascular risk in certain patient populations. Hikma’s Abbreviated New Drug Application (“ANDA”) for generic icosapent ethyl included a Section viii statement that Hikma was not seeking approval for the patented cardiovascular indication along with a “skinny label” that included only the indication for severe hypertriglyceridemia.
Client Alert | 1 min read | 04.09.25
Client Alert | 12 min read | 04.09.25
Client Alert | 4 min read | 04.07.25
